lifirafenib,mirdametinib
springworks therap,beigene,springworks therapuetics
['lifirafenib', 'mirdametinib', 'beigene', 'springworks']
updated clinical data from phase 1b trial of raf dimer inhibitor, lifirafenib, in combination w/ our mek inhibitor, mirdametinib presented today at #aacr23. 
At SpringWorks, we bring tenacity to work every day because patients need answers now.